{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:39:58Z","timestamp":1786466398628,"version":"build-2736575974"},"reference-count":62,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Ruxolitinib is widely used in polycythemia vera (PV) following hydroxyurea failure. However, validated response criteria to predict long-term outcomes in ruxolitinib-treated patients are lacking, complicating clinical decision-making. We investigated predictors of event-free survival ([EFS]; including progression to post-PV myelofibrosis, thrombosis, hemorrhages, or death) after 6 months of ruxolitinib in 178 patients with PV enrolled in the observational PV-ARC study. After a median follow-up from ruxolitinib start of 3.50 years, 15 patients died, 7 had a thrombosis, 9 had a hemorrhage, and 21 progressed to myelofibrosis. Overall, 5-year EFS was 70.4%. Leukocytosis, thrombocytosis, phlebotomy need, lack of spleen length reduction \u226550% (SR50), and ruxolitinib dose &amp;lt;10 mg twice daily at 3 time points (baseline and months 3 and 6), were tested for association with EFS. Multivariable analysis identified 3 independent risk factors: (1) ruxolitinib dose &amp;lt;10 mg twice daily at \u22651 time point (hazard ratio [HR], 1.94; P = .047), (2) no SR50 at months 3 and 6 (HR, 2.65; P = .009), (3) phlebotomy requirement at \u22652 time points (HR, 2.11; P = .039). Points were assigned as follows: 1 to phlebotomies at 1 time point; 2 to phlebotomies at \u22652 time points and to ruxolitinib &amp;lt;10 mg twice daily at \u22651 time point; and 2.5 to lack of SR50. Based on cumulative scores, we developed the PV\u2013response to ruxolitinib after 6 months (PV-RR6) prognostic model, identifying 3 risk categories: low (score 0: 5-year EFS, 89.4% [n = 63]), intermediate (score 1-2.5: EFS, 71.0% [n = 82]), and high (score &amp;gt;2.5: EFS, 38.9% [n = 33]). PV-RR6 enables early identification of patients at risk of poor outcomes, supporting timely treatment optimization in ruxolitinib-treated patients. This trial was registered at www.clinicaltrials.gov as NCT06134102.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020255","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:14:08Z","timestamp":1781201648000},"page":"5469-5479","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"2Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[{"name":"3Ematologia, Ospedale Businco, Universit\u00e0 degli Studi di Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"4Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy"},{"name":"5Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Elli","sequence":"additional","affiliation":[{"name":"6Divisione di Ematologia e Unit\u00e0 Trapianto di Midollo, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-5691","authenticated-orcid":false,"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"7Hematology Unit, Ospedale Belcolle, Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-5109","authenticated-orcid":false,"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[{"name":"8Hematology Section, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4453-6985","authenticated-orcid":false,"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[{"name":"9Hematology Unit, Department of Clinical and Molecular Sciences, Universit\u00e0 Politecnica delle Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[{"name":"10Unit of Hematology and Clinical Immunology, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6339-632X","authenticated-orcid":false,"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"11U.O.C. di Ematologia, Department of Hemato-Oncology, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-9654","authenticated-orcid":false,"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[{"name":"13University Hematology Division, Citta\u0300 della Salute e della Scienza Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Azienda Ospedaliera \u201cBianchi Melacrino Morelli,\u201d Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"D\u2019Addio","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Onco-Hematologic Department, Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"16Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-4791","authenticated-orcid":false,"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[{"name":"17Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[{"name":"18Haematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5819-9476","authenticated-orcid":false,"given":"Fabrizio","family":"Cavalca","sequence":"additional","affiliation":[{"name":"6Divisione di Ematologia e Unit\u00e0 Trapianto di Midollo, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"19Division of Cellular Biotechnologies and Hematology, University Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Onco-Hematologic Department, Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"8Hematology Section, Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"20Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia,\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"21Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"4Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy"},{"name":"5Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"19Division of Cellular Biotechnologies and Hematology, University Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4926-2727","authenticated-orcid":false,"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[{"name":"2Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"9","key":"2026081110270955600_bib1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2026081110270955600_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2024.2438996","article-title":"Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices","volume":"41","author":"Lyons","year":"2025","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2026081110270955600_bib3","doi-asserted-by":"crossref","first-page":"e70106","DOI":"10.1002\/hem3.70106","article-title":"Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: insights from the Landmark 2.0 global health survey","volume":"9","author":"Harrison","year":"2025","journal-title":"Hemasphere"},{"issue":"4","key":"2026081110270955600_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41375-025-02524-7","article-title":"Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)","volume":"39","author":"Manz","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2026081110270955600_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann Hematol"},{"issue":"7","key":"2026081110270955600_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/biomedicines11071925","article-title":"Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the polycythemia vera\u2014advanced integrated models (PV-AIM) project","volume":"11","author":"Verstovsek","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"2026081110270955600_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2026081110270955600_bib8","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2026081110270955600_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41375-025-02660-0","article-title":"A molecular signature predicts hematologic evolution in polycythemia vera patients","volume":"39","author":"Mansier","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"2026081110270955600_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3324\/haematol.2023.283987","article-title":"Pathogenesis and management of high molecular risk myeloproliferative neoplasms","volume":"110","author":"Ling","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"2026081110270955600_bib11","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"Tefferi","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2026081110270955600_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.2830170402","article-title":"Treatment of polycythemia vera with hydroxyurea","volume":"17","author":"Donovan","year":"1984","journal-title":"Am J Hematol"},{"issue":"12","key":"2026081110270955600_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis","volume":"104","author":"Ferrari","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2026081110270955600_bib14","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00432-021-03855-5","article-title":"Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera","volume":"148","author":"Crodel","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2026081110270955600_bib15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026081110270955600_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2026081110270955600_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41375-020-0849-2","article-title":"Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea","volume":"35","author":"Alvarez-Larr\u00e1n","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2026081110270955600_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2026081110270955600_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41408-023-00960-1","article-title":"The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients","volume":"13","author":"Barbui","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026081110270955600_bib20","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00277-024-05735-7","article-title":"Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice","volume":"103","author":"Chojecki","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2026081110270955600_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/rth2.12325","article-title":"Hematocrit and incidence of venous thromboembolism","volume":"4","author":"Folsom","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2026081110270955600_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/VHRM.S429995","article-title":"Diagnosis and management of cardiovascular risk in patients with polycythemia vera","volume":"19","author":"Benevolo","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"2026081110270955600_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clml.2022.11.011","article-title":"SOHO state of the art updates and next questions | polycythemia vera: is it time to rethink treatment?","volume":"23","author":"Mora","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2026081110270955600_bib24","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/10428194.2025.2523477","article-title":"Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement","volume":"66","author":"Bonifacio","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026081110270955600_bib25","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(22)00139-9","article-title":"Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance","volume":"9","author":"Venugopal","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026081110270955600_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026081110270955600_bib27","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026081110270955600_bib28","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026081110270955600_bib29","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-024-05704-0","article-title":"Ruxolitinib adherence in myelofibrosis and polycythemia vera: the \u201cRAMP\u201d Italian multicenter prospective study","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann Hematol"},{"issue":"13","key":"2026081110270955600_bib30","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"},{"issue":"10","key":"2026081110270955600_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.clml.2020.05.019","article-title":"Real-world outcomes of ruxolitinib treatment for polycythemia vera","volume":"20","author":"Coltoff","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026081110270955600_bib32","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2025-2826","article-title":"Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: a real-world analysis of the Medicare fee-for-service claims database","volume":"146","author":"Pemmaraju","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026081110270955600_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2026081110270955600_bib34","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1002\/cncr.70062","article-title":"Revised \u201ciRR6\u201d model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib","volume":"131","author":"Palandri","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"2026081110270955600_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"20","key":"2026081110270955600_bib36","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet Consensus Conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2026081110270955600_bib37","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.3390\/cancers15143706","article-title":"Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia VERA patients: a real-world PV-NET study","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026081110270955600_bib38","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026081110270955600_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026081110270955600_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7326\/0003-4819-88-3-424","article-title":"The International Classification of Diseases: ninth revision (ICD-9)","volume":"88","author":"Slee","year":"1978","journal-title":"Ann Intern Med"},{"key":"2026081110270955600_bib41","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Accessed 20 June 2024. https:\/\/www.meddra.org\/."},{"issue":"6","key":"2026081110270955600_bib42","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ije\/dyv337","article-title":"Cohort profile: the Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology","volume":"44","author":"Tsao","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"9","key":"2026081110270955600_bib43","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"19","key":"2026081110270955600_bib44","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026081110270955600_bib45","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"2026081110270955600_bib46","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","article-title":"Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea","volume":"39","author":"Palandri","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"2026081110270955600_bib47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2026081110270955600_bib48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/ejh.14124","article-title":"Ruxolitinib in patients with polycythemia vera resistant and\/or intolerant to hydroxyurea: European observational study","volume":"112","author":"Theocharides","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"2026081110270955600_bib49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00277-022-04815-w","article-title":"Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group","volume":"101","author":"Pepe","year":"2022","journal-title":"Ann Hematol"},{"issue":"11","key":"2026081110270955600_bib50","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/j.clml.2021.06.023","article-title":"Real-world dosing patterns of ruxolitinib in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea","volume":"21","author":"Altomare","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2026081110270955600_bib51","doi-asserted-by":"crossref","first-page":"e35801","DOI":"10.1002\/cncr.35801","article-title":"Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: interim results of the Italian observational study (ROMEI)","volume":"131","author":"Breccia","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"2026081110270955600_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.19812","article-title":"The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries","volume":"206","author":"Breccia","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"2026081110270955600_bib53","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2026081110270955600_bib54","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","article-title":"Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann Hematol"},{"key":"2026081110270955600_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb Res"},{"issue":"12","key":"2026081110270955600_bib56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency &gt;50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"19","key":"2026081110270955600_bib57","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.2022015680","article-title":"Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth","volume":"139","author":"Gotlib","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026081110270955600_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"key":"2026081110270955600_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.08.002","article-title":"Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia","volume":"218","author":"Janjetovic","year":"2022","journal-title":"Thromb Res"},{"key":"2026081110270955600_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2026081110270955600_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41572-025-00608-3","article-title":"Polycythaemia vera","volume":"11","author":"Harrison","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026081110270955600_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5469\/2536694\/blooda_adv-2026-020255-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5469\/2536694\/blooda_adv-2026-020255-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:14Z","timestamp":1786462994000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5469\/569099\/A-dynamic-prognostic-model-for-polycythemia-vera"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":62,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020255","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,8,3]]}}}